Accelero Biostructures

Accelero Biostructures is a private, service-oriented biotech company founded in 2012 (operationally from 2015) and headquartered in San Francisco. It provides high-throughput protein X-ray crystallography services through its ABS-Services℠ and ABS-OneStep℠ platforms to support fragment-based and structure-based drug discovery (SBDD) for pharma, biotech, and academia. The company's core value proposition is speeding up the structural biology workflow, particularly for challenging targets like biologics and antibodies, by applying industrialized processes developed during the Protein Structure Initiative. Its leadership team has deep expertise from Stanford/SLAC and Berkeley/LBNL, positioning it as a specialized CRO in the growing structural biology market.

High-throughput protein X-ray crystallography platforms (ABS-Services℠, ABS-OneStep℠) encompassing gene-to-structure pipeline, including protein production, crystallization, synchrotron data collection, and structure solution, augmented by bioinformatics.

Accelero competes with other specialized structural biology CROs and the internal capabilities of large pharma. Its key differentiator is its industrialized high-throughput crystallography pipeline derived from the Protein Structure Initiative. Broader competition includes general CROs and academic core facilities, but Accelero's focus on speed and proven track record targets the premium service segment.